MY ACCOUNT | NEWSLETTER |

Meridian to merge with SD Biosensor and SJL Partners


Meridian Bioscience, Inc., and SD Biosensor, Inc., will merge with SJL Partners LLC. As part of the deal, SD Biosensor and SJL Partners will combine to create “the Consortium” and purchase Meridian. 

“We are pleased to be a family with Meridian Bioscience as a great partner for accelerating our entry into the US IVD market,” said Dr. Young Shik Cho, chairman of SDB and representative of the Consortium. “I believe that SD Biosensor's R&D capabilities and mass production know-how, Meridian Bioscience's U.S. distribution network and expertise in the regulated U.S. market, and SJL Partners' strong management expertise will enable compelling synergies."

The sale of Meridian, a diagnostic testing solution and life sciences materials company, is slated to be an all-cash purchase of about $1.53 billion. Shareholders are expected to receive $34 cash per share, marking a 32% premium over the price of the stock at closing the day before the Consortium’s offer (March 17, 2022 when Meridian stock was priced at $25.67). The stock price is also 16% premium to the 1 month (starting June 7, 2022) average price of common stock.

"This announcement follows an extensive and deliberate review of Meridian's growth and value creation opportunities in the context of the broader macroeconomic and industry environment,” said John C. McIlwraith, chairman of Meridian. “In consultation with external financial advisors and following outreach to potential strategic and financial partners, the Board unanimously agreed that this transaction represents the best path forward for Meridian shareholders, providing them with immediate, compelling and certain value, while enabling the company to benefit from SDB's and SJL's capital support, expertise and experience."

The transaction is expected to close in the fourth quarter of 2022. At that time, it is anticipated SDB will own about 60% and SJL about 40% of Meridian. 

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Predictive utility of computed tomography-derived renal parenchymal volume for long-term postoperative renal function in cats with hydronephrosis.

Like0
Dislike0

Medical management and endoscopic biliary stenting associated with improved outcomes compared with surgery for extrahepatic biliary duct obstructions in dogs.

Like0
Dislike0

High-metacarpal deep digital flexor tenotomy and Steward clog shoeing for managing chronic refractory laminitis A retrospective clinical study.

Like0
Dislike0

Aoudad Could Spread Deadly Disease To Bighorn Populations

Like0
Dislike0

Medical Supplies and Services News

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top